Lv3
330 积分 2025-02-25 加入
PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC)
3小时前
已关闭
Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system
7天前
已完结
Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial
7天前
已完结
Association Between Cancer Incidence and Mortality in Web-Based Data in China: Infodemiology Study
14天前
已完结
Estimating the economic burden of colorectal cancer in China, 2019–2030: A population‐level prevalence‐based analysis
14天前
已完结
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
15天前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
15天前
已完结
An empirical investigation into concerns over quality-adjusted life-years: A review of cost-effectiveness analyses in oncology
1个月前
已关闭
Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force
1个月前
已完结
皖公网安备34019202002308
